WO2004047717A2 - Topical application of curcumin for the treatment of peripheral neuropathy - Google Patents

Topical application of curcumin for the treatment of peripheral neuropathy Download PDF

Info

Publication number
WO2004047717A2
WO2004047717A2 PCT/EG2003/000011 EG0300011W WO2004047717A2 WO 2004047717 A2 WO2004047717 A2 WO 2004047717A2 EG 0300011 W EG0300011 W EG 0300011W WO 2004047717 A2 WO2004047717 A2 WO 2004047717A2
Authority
WO
WIPO (PCT)
Prior art keywords
neuropathy
curcumin
extract
capsaicin
treatment
Prior art date
Application number
PCT/EG2003/000011
Other languages
French (fr)
Other versions
WO2004047717A3 (en
Inventor
I. Ahmed Elmallah
A. I. Mohamed Ibrahim
Abdellatif Mahmoud Selim Hanaa
Saied Hafiz Gazareen Sanaa
Original Assignee
Elmallah I Ahmed
Ibrahim A I Mohamed
Abdellatif Mahmoud Selim Hanaa
Saied Hafiz Gazareen Sanaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elmallah I Ahmed, Ibrahim A I Mohamed, Abdellatif Mahmoud Selim Hanaa, Saied Hafiz Gazareen Sanaa filed Critical Elmallah I Ahmed
Priority to AU2003285281A priority Critical patent/AU2003285281A1/en
Publication of WO2004047717A2 publication Critical patent/WO2004047717A2/en
Publication of WO2004047717A3 publication Critical patent/WO2004047717A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • Peripheral neuropathy in general and diabetic neuropathy in particular is a major concern in medicine.
  • a lot of patients suffer form peripheral neuropathy, specially diabetic patients type I and II
  • Current remedies include either topical application of capsaicin creams with different concentrations or administration of systemic drug with a property of pain killing or anti- inflammatory activity.
  • This invention comprises the use of topical curcumin ( 0.025-2%) alone or curcumin ( 0.025-2%) plus capsaicin ( 0.025-0.075%) for the treatment and alleviation of symptoms of peripheral neuropathy of different etiology including peripheral diabetic neuropathy.
  • the topical preparation may be in the form of cream, gel, ointment, powder, or solution. Sprayed or not sprayed

Abstract

Topical application of Curcumin (from Curcuma longa, Turmeric) is proved to be very effective in treating peripheral neuropathies, including diabetic neuropathy associated with chronic type I or Type II diabetes mellitus. Concentrations of 0.025-2% Curcumin were effective. The topical application in the form of a cream, an ointment, a gel or a solution.

Description

TITLE OF INVENTION Topical application of Curcumin or Curcumin plus Capsaicin for peripheral neuropathy.
Technical Field
Treatment and alleviation of the symptoms and complications associated with peripheral neuropathy specially diabetic neuropathies by topical application of remedy.
Background Art
Peripheral neuropathy in general and diabetic neuropathy in particular is a major concern in medicine. A lot of patients suffer form peripheral neuropathy, specially diabetic patients type I and II
Current remedies include either topical application of capsaicin creams with different concentrations or administration of systemic drug with a property of pain killing or anti- inflammatory activity.
The outcome of treatment is variable and a considerable numbers of treated patients get at least some benefit of either treatments. Systemic remedies, however, is associated with adverse systemic effects.
Disclosure of invention:
This invention comprises the use of topical curcumin ( 0.025-2%) alone or curcumin ( 0.025-2%) plus capsaicin ( 0.025-0.075%) for the treatment and alleviation of symptoms of peripheral neuropathy of different etiology including peripheral diabetic neuropathy.
The topical preparation may be in the form of cream, gel, ointment, powder, or solution. Sprayed or not sprayed
The formulated drug is applied topically on the affected area twice or more daily for a period ranging from days to months according to the getting beneficial effect
This regimen resulted in disappearance of all or at least most of the symptoms associated with peripheral neuropathy. This was compared to placebo formula containing only the formula inactive base.
Best mode of carrying out the invention:
1 - Preparation of cream, ointment or gel, containing either pure curcumin or extract of the herbal plant Curcuma longa (turmeric) with a concentration of 0.025-2% curcumin content. - Preparation of cream, ointment or gel containing a combination of curcumin ( or the extract of curcuma longa) in a concentration of 0.025-2% and Capsaicin ( or capsicum extract in a concentration of 0.025-0.075% - Preparation of cream, ointment or gel containing a combination of curcumin ( or the extract of curcuma longa) in a concentration of 0.025-2% and other pain killer or anti-inflammatory agents with in appropriate concentrations.

Claims

CLAIMS - We are the first to prove the efficacy and beneficial effect of the extract of Curcuma longa (turmeric) as such or the pure active ingredients which known collectively as curcuminoids or curcumin in the treatment of peripheral neuropathies especially diabetic neuropathy, herpatic neuropathy and other symptoms of peripheral neuritis. - We are the first to prove the efficacy of topical application of formula containing curcumin or the extract of Curcuma longa (turmeric) in a concentration of 0.025-2% in alleviation and treatment of symptoms of peripheral neuropathies associated with or as a result of any organic disease. - Topical application may be in the from of cream, ointment, gel, powder, solution. Sprayed or not sprayed. - The use of combination of Curcumin or Capsaicin in different concentration for treatment of peripheral neuropathies associated with or as a result of organic disease - Peripheral neuropathy include 1- A classical term for any disorder affecting any segment of the nervous system. 2. In contemporary usage, a disease involving the cranial or spinal nerves, asymmetric motor neuropathy, brachial plexus neuropathy, diabetic neuropathy, diphtheritic neuropathy, entrapment neuropathy sensory radicular neuropathy, drug-induced neuropathy, distal neuropathy, vitamin B12 neuropathy - The term curcumin is meant by curcumin, curcuma longa extract, curcuminoids, turmeric extract or any of the ingredients of curcuma longa extract. - The term capsaicin is meant by capsaicin pure, extract of capsicum, capsicum oleoresin. And include the one obtained from any herbal source. - The concentration range for the effective curcumin in the topical preparations ranges from 0.025-2% and that of capsaicin from 0.025-2%
PCT/EG2003/000011 2002-11-25 2003-11-23 Topical application of curcumin for the treatment of peripheral neuropathy WO2004047717A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003285281A AU2003285281A1 (en) 2002-11-25 2003-11-23 Topical application of curcumin for the treatment of peripheral neuropathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2002111270 2002-11-25
EG2002111270A EG23547A (en) 2002-11-25 2002-11-25 Preparation of a topical pharmaceutical preparation of curcumin alone or a combination of circumin plus capsaicin as an effective remedy for treatmentof peripheral neuropathies

Publications (2)

Publication Number Publication Date
WO2004047717A2 true WO2004047717A2 (en) 2004-06-10
WO2004047717A3 WO2004047717A3 (en) 2004-09-23

Family

ID=32946815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2003/000011 WO2004047717A2 (en) 2002-11-25 2003-11-23 Topical application of curcumin for the treatment of peripheral neuropathy

Country Status (3)

Country Link
AU (1) AU2003285281A1 (en)
EG (1) EG23547A (en)
WO (1) WO2004047717A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125830A3 (en) * 2011-03-16 2012-11-15 Signpath Pharma, Inc. Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
US9138411B2 (en) 2012-08-31 2015-09-22 University Of North Texas Health Science Center At Fort Worth Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
WO2016157053A1 (en) * 2015-03-31 2016-10-06 Kolinpharma S.P.A. A composition for the treatment of neuropathies and/or neuropathic pain
US9682041B2 (en) 2011-06-03 2017-06-20 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
IT201700088621A1 (en) * 2017-08-01 2019-02-01 Inpha Duemila Srl Food supplements for use in the treatment of diseases associated with alterations of peripheral nerve trophism.
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10668123B2 (en) 2015-04-27 2020-06-02 Omniactive Health Technologies Limited Capsicum compositions and uses thereof
US11806401B2 (en) 2016-04-27 2023-11-07 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246398A (en) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd Prophylactic or therapeutic agent for disorder caused by increment of lipoperoxide in vivo
JPH11246399A (en) * 1998-03-03 1999-09-14 Lion Corp Lipid metabolism improving composition

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
WO2012125830A3 (en) * 2011-03-16 2012-11-15 Signpath Pharma, Inc. Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US9682041B2 (en) 2011-06-03 2017-06-20 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10617639B2 (en) 2011-06-03 2020-04-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10357458B2 (en) 2011-06-03 2019-07-23 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US9138411B2 (en) 2012-08-31 2015-09-22 University Of North Texas Health Science Center At Fort Worth Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10413526B2 (en) 2015-03-31 2019-09-17 Kolinpharma S.P.A. Composition for the treatment of neuropathies and/or neuropathic pain
WO2016157053A1 (en) * 2015-03-31 2016-10-06 Kolinpharma S.P.A. A composition for the treatment of neuropathies and/or neuropathic pain
US10668123B2 (en) 2015-04-27 2020-06-02 Omniactive Health Technologies Limited Capsicum compositions and uses thereof
US11806401B2 (en) 2016-04-27 2023-11-07 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
EP3437638A1 (en) * 2017-08-01 2019-02-06 Inpha Duemila S.r.l. Nervonic acid and curcumin for the treatment of pathologies associated with peripheral nerves trophism alterations
IT201700088621A1 (en) * 2017-08-01 2019-02-01 Inpha Duemila Srl Food supplements for use in the treatment of diseases associated with alterations of peripheral nerve trophism.

Also Published As

Publication number Publication date
AU2003285281A8 (en) 2004-06-18
AU2003285281A1 (en) 2004-06-18
WO2004047717A3 (en) 2004-09-23
EG23547A (en) 2006-05-10

Similar Documents

Publication Publication Date Title
Bedi et al. Herbal therapy in dermatology
Taheri et al. Herbs in dentistry
WO2004047717A2 (en) Topical application of curcumin for the treatment of peripheral neuropathy
JP2002512971A (en) Topical substance mixture containing olive oil and honey
CA2518965A1 (en) Homeopathic formulations useful for treating pain and/or inflammmation
Sailer et al. Pharmaceutical and medicinal aspects of Australian tea tree oil
JP6966998B2 (en) Formulations for the treatment of oral, throat and airway disorders
EP3212288A1 (en) Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract
BR0006024A (en) Composition for the treatment of inflammation and pain in mammals
Maleš et al. Application of medicinal plants in several dermatovenerological entities
CN1921873B (en) Coriander oil and preparations which have antimicrobial and antiphlogistic effects and which contain said oil and use thereof
JP2012504624A (en) Topical treatment of skin infections
US8962045B2 (en) Herbal/organic composition for the management of pain
US9095607B2 (en) Gel for topical application of clove essential oil with broad spectrum anti-inflammatory action and method of preparing same
US9028888B2 (en) Compositions and methods for treatment and management of pain
Teymouri et al. The comparative effect of hydro alcoholic and hydro distillation extracts of Melissa officinalis on acne and pimple
Ali Use of acacia gum in the treatment of skin lesions of two children with Kwashiorkor
US11318182B1 (en) Plant extract for skin infections
US20080045604A1 (en) Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations
Sharma et al. Evaluation of the efficacy and safety of Rumalaya gel in the management of acute and chronic inflammatory musculoskeletal disorders: An open, prospective, noncomparative, phase III clinical trial'
RU2762506C1 (en) Agent for applying oral and nasal cavities and method for its use as part of complex therapy of infectious and inflammatory diseases of nasal and oral cavities
KR101548254B1 (en) Composition for treating skin disease comprising sulfur, alum and vinegar
Chase et al. Solasodine Glycosides from the Eggplant in a Topical Cream Psorend BEC Are Effective against Psoriasis
DE4314131C2 (en) Use of Equisetum to fight psoriasis
DE4244754C2 (en) Combating the pathogens of dermatomycoses in clothing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP